ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report - Hagens Berman

ABL Investors with Losses Encouraged to Contact Hagens Berman

SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Abacus Global Management, Inc. (NASDAQ: ABL) is under mounting pressure as its stock continues to slide, driven by a series of damning reports from Morpheus Research-a newly formed investigative group led by analysts who previously worked at the renowned Hindenburg Research. Despite Abacus's public denials and the announcement of a $20 million share repurchase program, investor confidence remains shaken, with shares now down more than 36% over the past month.

Prominent law firm Hagens Berman has launched its own investigation into the claims raised by Morpheus Research. The firm is encouraging damaged Abacus shareholders to report their financial losses now. The firm is also seeking information from individuals who may possess relevant knowledge to aid in their probe.

Visit: www.hbsslaw.com/investor-fraud/abl

Contact the Firm Now: ABL@hbsslaw.com
844-916-0895

Morpheus Research: Hindenburg's Legacy Continues:

Morpheus Research emerged in early 2025, quickly gaining credibility due to its team's roots in Hindenburg Research-the short-selling firm known for uncovering major corporate scandals. Hindenburg's track record includes exposing alleged fraud or misconduct at high-profile companies such as Nikola Corporation, Clover Health, and Lordstown Motors, often resulting in regulatory investigations, executive resignations, and billions in lost market value for the targeted firms.

Escalating Allegations Against Abacus

The scrutiny on Abacus began on June 4, 2025, when Morpheus published its first report, accusing the company of manipulating its life settlements portfolio through aggressive mark-to-model accounting and questionable life expectancy estimates provided by Lapetus Solutions. Morpheus claimed these practices resulted in inflated asset values and "fake revenue," allegations that triggered a sharp 20% single-day drop in Abacus's share price.

Abacus responded by retaining independent actuarial firm Lewis & Ellis to review its balance sheet and attempted to reassure investors of its compliance with accounting standards. However, Morpheus's follow-up report on June 12 intensified the controversy, alleging that Abacus's rebuttal was inconsistent with its own SEC filings and introducing new claims of undisclosed related-party transactions and "Carlisle Round-Tripping Policies" involving company insiders. Morpheus also questioned the independence of Lewis & Ellis, citing their prior involvement in other disputed valuations.

Stock Slide Continues Despite Company Initiatives

In an effort to restore confidence, Abacus's board authorized a $20 million share repurchase program to be executed over the next 18 months, intending to signal management's belief in the company's long-term value. Despite these measures and repeated denials of wrongdoing, the company's stock has continued to trade near its 52-week low, falling more than 36% over the past month.

Hagens Berman's Investigation

Hagens Berman is actively investigating whether Abacus Global Management misled investors regarding the valuation of its assets and the independence of the third-party actuarial firm Lewis & Ellis, which purportedly vetted those valuations.

Reed Kathrein, partner at Hagens Berman leading the investigation, stated, "We are committed to thoroughly examining the allegations against Abacus and holding accountable those who may have misrepresented the company's financial health. Investors deserve transparency and the truth."

Investors affected by the decline in Abacus's stock price are urged to submit their losses now so that the firm may assess their rights and potential claims. The firm has a strong history of securing substantial recoveries in complex securities fraud cases and is prepared to pursue all available legal remedies on behalf of harmed shareholders.

If you'd like more information and answers to frequently asked questions about the Abacus Global investigation, read more ยป

Whistleblowers: Persons with non-public information regarding Abacus Global Management should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ABL@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.